DonaldLeeLammMD

PubMed

• 431 citations
  A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder.
  Donald L. Lamm, Brent A. Blumenstein, E. D. Crawford, Montie Je, Scardino P
  The New England Journal of Medicine. 1991-10-24
• 165 citations
  A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer
  James M. Burke, Donald L. Lamm, Maxwell V. Meng, John Nemunaitis, Joseph J. Stephenson
  The Journal of Urology. 2012-12-01
• 85 citations
  DNA Based Therapy with Diphtheria Toxin-A BC-819: A Phase 2b Marker Lesion Trial in Patients with Intermediate Risk Nonmuscle Invasive Bladder Cancer
  Ofer N. Gofrit, Shalva Benjamin, Sarel Halachmi, Ilan Leibovitch, Zohar A. Dotan
  The Journal of Urology. 2014-06-01

Journal Articles

• Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer.  
  Colombel M, Soloway M, Akaza H, Bohle A, Palou J, Buckley R, Lamm DL, Brausi M, Witjes JA, Persad R, Eur Urol sup. 7: 618–626
• The potential application of Allium sativum (garlic) for the treatment of bladder cancer.  
  Lamm DL and Riggs DR, Urol Clin North Am 27(1): 157-162
• Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncol...  
  Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, and Crawford ED, J Urol 163(4): 1124-1129
• Efficacy and safety of bacille Calmette-Guerin immunotherapy in superficial bladder cancer.  
  Lamm DL, Clin Infect Dis.31 Suppl 3:S86-90
• Current trends in bladder cancer treatment.  
  Lamm DL, Allaway M, Ann Chir Gynaecol. 89:234-41
• Smoking and renal cell carcinoma.  
  Hogan TF, Lamm DL, Ducatman AM, W V Med J. 97:32-5
• Metallothionein isoform 1 and 2 gene expression in the human bladder: evidence for upregulation of MT-1X mRNA in bladder cancer.  
  Somji S, Sens MA, Lamm DL, Garrett SH, Sens DA, Cancer Detect Prev. 25:62-75
• Immunotherapy for bladder cancer.  
  Kamat AM, Lamm DL, Curr Urol Rep. 2(1):62-9
• Management of stage T1 tumors of the bladder: International Consensus Panel.  
  Nieder AM, Brausi M, Lamm D, O'Donnell M, Tomita K, Woo H, Jewett MA, Urology. 66(6 Suppl 1):108-25
• Is a second transurethral resection necessary in T1 bladder cancer?  
  Lamm DL, Clin Pract Urol. 4(1):12-3
• Bladder cancer: improving care with better classification and risk stratification.  
  Lamm D, J Urol. 178(4 Pt 1):1146-7
• Clinical Practice Recommendations for the Management of Non–Muscle Invasive Bladder Cancer.  
  Lamm DL, Colombel M, Persad R, Soloway M, Bohle A, Palou J, Witjes JA, Akaza H, Buckley R, Brausi M, Eur Urol sup. 7:651–666
• Bacillus Calmette-Guerin Immunotherapy Significantly Prolongs Survival of Animals with Prostate Cancer.  
  Lamm DL, Riggs DR, Donley MS, White J, Yeater R, and Bryner RW, The Prostate Journal 1(4): 190-194
• Diagnosis of Non-Muscle Invasive Bladder Cancer.  
  Palou J, Böhle A, Witjes JA, Colombel M, Brausi M, Lamm DL, Persad R, Buckley R, Akaza H, Soloway M, Eur Urol sup. 7: 627-636
• Current Approaches to the Management of Non-Muscle Invasive Bladder Cancer: Comparison of Current Guidelines and Recommendations.  
  Persad R, Lamm DL, Brausi M, Soloway M, Palou J, Böhle A, Colombel M, Akaza H, Buckley R, Witjes JA, Eur Urol sup. 7: 637-650
• Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy–Associated Adverse Events.  
  Witjes JA, Palou J, Soloway M, Lamm DL, Brausi M, Spermon JR, Persad R, Buckley R, Akaza H, Colombel M, Böhle H, Eur Urol sup. 7: 667-674
• Phase I/II marker lesion study of intravesical BC-819 DNA plasmid in H19 over expressing superficial bladder cancer refractory to bacillus Calmette-Guerin.  
  Sidi AA, Ohana P, Benjamin S, Shalev M, Ransom JH, Lamm D, Hochberg A, Leibovitch I, J Urol. 180(6):2379-83
• An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-musc...  
  Lamm D, Böhle A, Palou J, Persad R, Brausi M, Colombel M, Akaza H, Buckley R: Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al, Eur Urol 56:247-56
• An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-musc...  
  Lamm D, Böhle A, Palou J, Persad R, Brausi M, Colombel M, Akaza H, Buckley R: Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al, Eur Urol. 57(2):e7-9
• Tumor implantation: a rare but potentially preventable cause of death in cystectomy patients. Tumor implantation: a rare but potentially preventable cause of death in ...  
  Via KJ, Burns KM, Lamm DL, Can J Urol. 17(3):5216-8
• Bladder Cancer Genitourinary Oncology Study Group. Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins du...  
  Nepple KG, Lightfoot AJ, Rosevear HM, O'Donnell MA, Lamm DL, J Urol. 184(5):1915-9
• Impact of smoking on outcomes after intravesical bacillus calmette-guérin therapy for urothelial carcinoma not invading muscle of the bladder.  
  Lamm DL, BJU Int. 108(4):530
• A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group.  
  Brausi M, Witjes JA, Lamm D, Persad R, Palou J, Colombel M, Buckley R, Soloway M, Akaza H, Böhle A, J Urol. 186(6):2158-67
• A randomized prospective comparison of oral versus intravesical and percutaneous Bacillus Calmette-Guérin for superficial bladder cancer.  
  Lamm DL, DeHaven JI, Shriver J, Crispen R, Grau D and Sarosdy MF, J Urol 144(1):65-67
• Bacillus Calmette-Guérin immunotherapy of the cancer-contaminated wound.  
  Lamm DL, Reichert DF, Radwin HM and Thor DE, . J Surg Res 27(1):14-22
• Join now to see all

Abstracts/Posters

• Adriamycin versus BCG in superficial bladder cancer: A Southwest Oncology Group Study.
  Lamm DL, Crissman J, Blumenstein B, et al, Prog Clin Biol Res 310(11):263-270